Shire appoints Susan Kilsby to succeed Matthew Emmens as chair
This article was originally published in Scrip
Matthew Emmens is retiring as non-executive chairman of Shire, and is being replaced following Shire's AGM on 29 April 2014 by Susan Kilsby, chairman of Shire's audit, compliance and risk committee since May 2013. She will step down from her previous role at that time, to be replaced by Dominic Blakemore. Mr Emmens joined the company as its CEO in 2003, and became chairman in 2008. Ms Kilsby joined the Shire board as a non-executive director in September 2011 following a career in investment banking. She will also become a member of Shire's nomination committee with effect from 1 February 2014.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.